United UATP, Powered by TreviPay, Expands Corporate Travel Billing Program to New Global Markets
10.3.2026 13:00:00 CET | Business Wire | Press release
Strategic market entry to Europe, Australia and New Zealand further strengthens United Airlines’ ability to serve agency and corporate customers with cost-free billing, flexible air travel payment options and enhanced reporting tools
UATP, the global network that enables organizations to simplify payment processes and expand their payment capabilities, today announced the expansion of United Airlines’ cost-free UATP billing program (“United UATP”), powered by TreviPay, to Europe, Australia and New Zealand.
This expansion opens new opportunities for corporate customers and travel agencies in these regions to access the benefits of United UATP, including cost-free, streamlined travel expense reconciliation.
Since 2015, United UATP has collaborated with TreviPay, a fully managed B2B payments platform, to power its streamlined solution for air travel payments in the U.S. and Canada. For companies currently benefitting from the United UATP billing program, TreviPay handles customer service, underwriting risk, and manages the processing, invoicing in local currencies, and accounts receivable automation, including disputes, collections and reconciliation. A consolidated invoice process provides streamlined access to Level III purchase data, enabling United to quickly and easily send customer invoices.
Commenting on the program expansion, Ralph Kaiser, President and CEO of UATP said, “Extending the reach of United’s long-standing program represents an important milestone for United UATP and our partners. Our goal has always been to empower airlines and their customers with innovative payment options, and this growth underscores the strength of United UATP as a platform designed for global corporate travel.”
Programs like United UATP are designed to eliminate time-consuming, manual order-to-cash processes by aligning with B2B buyer preferences for invoicing and net terms. A study of 300 global business buyers conducted by Murphy Research emphasized the need for airlines to offer choice of preferred payment methods, convenient onboarding and software integrations, and customization of invoicing. Other benefits of United UATP allow customers to:
- Purchase travel globally across all UATP acceptance channels
- Settle transactions in local currencies.
- Access Level III purchase data for simplified reconciliation and detailed reporting.
- Eliminate application, annual, transaction and currency conversion fees.
- Benefit from card-less account options and security features intended to help mitigate fraud risk.
“Payments are a powerful tool for airlines to drive sales and strengthen customer relationships,” said Brandon Spear, CEO of TreviPay. “This market expansion will allow United UATP to capitalize on commercial opportunities in new markets with seamless payment processes that drive loyalty, attract new customers, boost ticket sales and increase revenue.”
To learn more about the United UATP billing program powered by TreviPay, visit united.business/uatp. Visit TreviPay for additional information on the invoicing solution for travel management companies.
About UATP
Accepted as a form of payment for corporate business travel worldwide by airlines, travel agencies, and Amtrak®; UATP accounts are issued by: Aeromexico; AERTiCKET; Air Canada (TSE: AC); Air China; Air New Zealand (ANZFF.PK); Air Niugini; AirPlus International a wholly owned subsidiary of SEB Kort; Akbar Travels; American Airlines (NASDAQ: AAL); APG Airlines; APG Pay; Austrian Airlines; BCD Travel; China Eastern Airlines (NYSE: CEA); ConnexPay; Delta Air Lines (NYSE: DAL); EL AL Israel Airlines; Ethiopian Airlines; Etihad Airways; Fareportal; Flight Centre Travel Group; Frontier Airlines; GOL Linhas Aereas inteligentes S.A. (NYSE: GOL and Bovespa: GOLL4); Hahn Air; High Point Travel; Hopper; Japan Airlines (9201:JP); JetBlue Airways; LATAM Airlines; MakeMyTrip; Qantas Airways (QUBSF.PK); Shandong Airlines; Sichuan Airlines; Southwest Airlines; Sun Country Airlines; TUIfly GmbH; Turkish Airlines (ISE: THYAO); United Airlines (NASDAQ: UAL); Wego; WestJet; Wings Global Travel and W2 by GO7.
About TreviPay
TreviPay, The Pay by Invoice Company™, is a fully managed B2B payments platform for global brands. Proven to increase AOV and reduce DSO, our accounts receivable automation software, enhanced by AI, optimizes order-to-cash and integrates with all channels and ERPs. Delivering a superior payment experience, TreviPay is the choice of top retailers, manufacturers and travel companies. With more than four decades of experience powering over $8 Billion in global trade, TreviPay was named a Leader for Embedded Payment Applications by IDC and a top vendor in cash application by The Hackett Group. For more, visit www.trevipay.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260310043257/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom